A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors
The purpose of this study is to assess the safety and tolerability for the combination therapy of BMS-986205 and Nivolumab in patients with advanced tumors
Advanced Cancer
DRUG: BMS-986205|BIOLOGICAL: Nivolumab
Incidence of Adverse Events (AEs), Safety and Tolerability, 15 months|Incidence of Serious Adverse Events (SAEs), Safety and Tolerability, 15 months|Incidence of Death, Safety and Tolerability, 15 months|Incidence of Laboratory Abnormalities, Safety and Tolerability, 15 months|AEs leading to discontinuation, Safety and Tolerability, Up to one year
Maximum observed plasma concentration (Cmax), To characterize the Pharmacokinetics (PK) of BMS-986205 administered alone and in combination with nivolumab, Up to one year|Time of maximum observed plasma concentration (Tmax), To characterize the PK of BMS-986205 administered alone and in combination with nivolumab, Up to one year|Area under the plasma concentration-time curve in one dosing interval [AUC(TAU)], To characterize the PK of BMS-986205 administered alone and in combination with nivolumab, Up to one year|Trough observed plasma concentration at the end of the dosing interval (Ctrough), To characterize the PK of BMS-986205 administered alone and in combination with nivolumab, Up to one year|Apparent total body clearance (CLT/F), To characterize the PK of BMS-986205 administered alone and in combination with nivolumab, Up to one year|Apparent volume of distribution at steady-state (Vss/F), To characterize the PK of BMS-986205 administered alone and in combination with nivolumab, Up to one year|Percent urinary recovery over 24 hours (%UR24), To characterize the PK of BMS-986205 administered alone and in combination with nivolumab, Up to 24 hours|Biomarker Availability, To characterize the pharmacodynamic activity of BMS-986205 administered alone and in combination with nivolumab, Up to one year|Incidence of anti-drug antibody (ADA), To characterize the immunogenicity of nivolumab when administered in combination with BMS-986205, Up to one year|Best Overall Response (BOR), To investigate the preliminary anti-tumor activity of BMS-986205 administered in combination with nivolumab in advanced malignant tumors, Up to one year|Duration of Response (DOR), To investigate the preliminary anti-tumor activity of BMS-986205 administered in combination with nivolumab in advanced malignant tumors, Up to one year
The purpose of this study is to assess the safety and tolerability for the combination therapy of BMS-986205 and Nivolumab in patients with advanced tumors